Hera-MI
私たちについて
Breast cancer is the most common cancer in women, so early detection is vital. Hera-MI has made this its priority. Based in Nantes since 2017, Hera-MI has established itself as one of France's MedTech SMEs focusing on innovation in healthcare and artificial intelligence. Its commitment to healthcare is of general interest.
Hera-MI specializes in AI-based medical devices. These software solutions aim to facilitate the radiological diagnosis of breast cancer, improving the quality and accuracy of image interpretation.
Hera-MI's flagship product is its AI-based detection and diagnosis software, Breast-SlimView.
私たちの価値観
Hera-MI is focusing its research on artificial intelligence applied to medical imaging, with a particular emphasis on breast cancer diagnosis.
The company's aim is to meet tomorrow's healthcare challenges by improving the healthcare system experience through AI.
With this in mind, Hera-MI is developing software solutions to support medical decision-making, thus benefiting radiologists, senologists and patients. As patient care is of paramount importance, Hera-MI designs its AI with the aim of ensuring that patients obtain the most accurate result possible and at the earliest possible stage.
